Literature DB >> 8605486

Risk of diarrhoea due to Clostridium difficile during cefotaxime treatment. Cefotaxime compares favourably with other third generation cephalosporins.

E Rothschild, A Rauss, G Danan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8605486      PMCID： PMC2350484          DOI： 10.1136/bmj.312.7033.778

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime.

Authors:  M Impallomeni; N P Galletly; S J Wort; J M Starr; T R Rogers
Journal:  BMJ       Date:  1995-11-18

Review 2.  Community-acquired pneumonia.

Authors:  J G Bartlett; L M Mundy
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

Review 3.  Diagnosis and management of Clostridium difficile infection.

Authors:  S Tabaqchali; P Jumaa
Journal:  BMJ       Date:  1995-05-27

4.  Comparative toxicities of third-generation cephalosporins.

Authors:  B R Meyers
Journal:  Am J Med       Date:  1985-08-09       Impact factor: 4.965

Review 5.  Gram-positive superinfections following beta-lactam chemotherapy: the significance of the enterococcus.

Authors:  R N Jones
Journal:  Infection       Date:  1985       Impact factor: 3.553
  5 in total
  1 in total

Review 1.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.